ArticleCureus2025
Demographic and Clinicopathological Analysis of Leiomyosarcoma at Various Anatomical Sites: A Tertiary Care Hospital Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Leiomyosarcoma (LMS) is a malignant tumor of smooth muscle origin, most prevalent in soft tissues and the gynecologic tract. The molecular alteration associated with this condition is genomic instability, leading to complex genotypes. Aim This study aimed to study the demographic and histopathological profile of LMS cases (80 cases) diagnosed in our hospital over seven years. Materials and methods This is a retrospective study of histologically proven LMS cases from January 2017 to December 2023 using the laboratory information system from our institution. The variables to be studied included clinical demographic data and histopathological findings. Results Out of 80 cases studied, 45 were resected specimens, 25 were biopsies, and 10 were referral cases. Fifty-eight out of 80 cases were primary LMS, 17 were metastases from various sites, and five were recurrent lesions. The most common site of primary lesion was the uterus, with 26% (n=15), followed by the retroperitoneum, with 21% (n=12), and the thigh, with 12% (n=7). Infrequent sites included the prostate, intestine, omentum, kidney, and testis, each constituting about 2% (n=1), with a male:female ratio of 1:1.7 and a mean age of presentation of 55 years. The average size of the excised tumor ranged from 5.5 cm to 15 cm, and around 73% presented with histological grade 2. Almost all the cases tested for immunohistochemical (IHC) expression of smooth muscle actin (SMA) and desmin showed positivity, along with a median Ki-67 labeling index of 30%. Metastatic lesions were found primarily in the liver, lungs, and soft tissues and rarely in bone. Conclusion The results of our study witnessed the incidence of LMS at diverse anatomical locations and dimensions along with advanced grade at presentation that determined the overall prognosis, though uterine LMS tend to be more aggressive and are prone to metastasize. Hence, the comprehensive assessment at the time of diagnosis, along with close follow-up of the patients, is recommended for early detection and management of metastatic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.